指南与共识胸部肿瘤

ASCO指南:肺癌根治性治疗后影像与生物标志物监测

Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2019-12-12

ASCO专家组基于2000至2019年文献检索(14项相关研究)制定指南,针对I-III期非小细胞肺癌和小细胞肺癌根治性治疗后监测提出推荐。推荐每6个月影像监测2年、之后每年一次以发现新原发肺癌;胸部CT为最佳方式;不推荐FDG PET/CT、循环生物标志物作为监测策略;I-III期NSCLC不推荐脑MRI常规监测,小细胞肺癌可第一年每3个月、第二年每6个月脑MRI。

要点

  • I-III期肺癌根治后每6个月影像监测2年,之后每年一次。
  • 胸部CT是最佳监测手段,不推荐FDG PET/CT作为监测工具。
  • 循环生物标志物不用于复发监测;小细胞肺癌可定期脑MRI。

核心结论

  • I-III期NSCLC和SCLC根治性治疗后应定期影像监测,胸部CT为最佳方式。
  • FDG PET/CT和循环生物标志物不应作为监测策略。
  • 脑MRI不用于I-III期NSCLC常规监测,但可用于SCLC根治后定期监测。

研究设计与样本

  • ASCO召集多学科专家组进行文献检索,纳入2000至2019年系统综述、荟萃分析、随机对照试验及前瞻性和回顾性比较观察研究。
  • 文献检索共识别14项相关研究作为证据基础。
  • 专家组基于可用证据和非正式共识制定循证指南推荐。

主要发现

  • 文献检索识别14项相关研究用于制定监测推荐。
  • 关注结局包括生存、无病或无复发生存及生活质量。

关键数值与推荐

  • 复发监测影像:每6个月一次持续2年,之后每年一次以发现新原发肺癌。
  • 胸部CT是监测的最佳影像方式;FDG PET/CT不应作为监测工具。
  • 循环生物标志物不应作为监测策略用于检测复发。
  • I-III期NSCLC不推荐脑MRI常规监测;I-III期SCLC根治性治疗后第一年每3个月、第二年每6个月可脑MRI。
  • 对临床不适合或不愿接受进一步治疗的患者可不提供监测影像;年龄不应排除监测影像。

临床怎么用

  • 对I-III期肺癌根治性治疗后患者,按每6个月2年、之后每年一次安排胸部CT监测。
  • 避免使用FDG PET/CT或循环生物标志物作为常规监测手段。
  • SCLC根治后可按第一年每3个月、第二年每6个月进行脑MRI监测。
  • 不因年龄排除监测影像,但临床不适合或不愿进一步治疗者可不提供。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide evidence-based recommendations to practicing clinicians on radiographic imaging and biomarker surveillance strategies after definitive curative-intent therapy in patients with stage I-III non-small-cell lung cancer (NSCLC) and SCLC. METHODS: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2019. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 14 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Patients should undergo surveillance imaging for recurrence every 6 months for 2 years and then annually for detection of new primary lung cancers. Chest computed tomography imaging is the optimal imaging modality for surveillance. Fluorodeoxyglucose positron emission tomography/computed tomography imaging should not be used as a surveillance tool. Surveillance imaging may not be offered to patients who are clinically unsuitable for or unwilling to accept further treatment. Age should not preclude surveillance imaging. Circulating biomarkers should not be used as a surveillance strategy for detection of recurrence. Brain magnetic resonance imaging should not be used for routine surveillance in stage I-III NSCLC but may be used every 3 months for the first year and every 6 months for the second year in patients with stage I-III small-cell lung cancer who have undergone curative-intent treatment.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schneider BJ, Ismaila N, Aerts J, et al. Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline. J Clin Oncol. 2019. PMID: 31829901. doi:10.1200/JCO.19.02748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。